【摘要】 目的:观察国产羟基喜树碱(HCPT)为基础组成的HEP方案对多次化疗失败晚期乳腺癌患者的疗效及耐受性。方法:HEP方案(HCPT6mg/m2,静脉滴入,d1~d5;依托泊苷100mg,静脉滴入,d1~d5,或50mg/d,口服d1~d14;顺铂20mg,静脉滴入,d1~d5)治疗复发或转移后经至少一种化疗方案治疗失败的晚期乳腺癌患者,4周重复,治疗2~6个周期。结果:共25例患者接受治疗,其中25例可评价毒副反应,23例可评价疗效。有效率17·4%(4/23),临床受益率为56·5%(13/23),中位疾病进展时间(TTP)为7·0个月。主要不良反应为恶心、呕吐、脱发及骨髓抑制,其中Ⅲ~Ⅳ度白细胞下降占20·0%(5/25)。结论:HEP方案对先前反复化疗失败的晚期乳腺癌有一定疗效,是可选择的治疗方案之一。更多还原

【Abstract】 OBJECTIVE:To determine the efficacy and tolerance of HEP regimen in advanced breast cancer failed in chemotherapy previously. METHODS: The patients with pretreated breast cancer received HEP regimen （HCPT 6 mg/m²,d₁～d₅, etoposide Ⅳ 0.1 d₁～d₅,or etoposide oral 50 mg/d d₁～d 14 , cisplatin 20 mg d₁～d₅）, repeated 2～6 cycles each 4-week. RESULTS: Twenty-five patients were enrolled into the study. 25 patients were evaluated the toxicity, and 23 patients were evaluated the efficacy. The objective response rate was 17.4%（4/23）, and the clinical benefit response rate was 56.5%（ 13/23 ）,the mean Time to Progress （TTP） was 7.0 months. The main toxicities were nausea, vomiting, alopecie and myelosuppression. 20.0% of the 25 patients were grade 3 or 4 neutropenia. CONCLUSIONS: HEP regimen was modestly active in advanced breast cancer failed chemotherapy previously. It can be a choice for these patients.更多还原